Business Context and Reporting Period
Company: Trinity Biotech PLC
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2025
Filing Date: December 23, 2025
Principal Executive Office: IDA Business Park, Bray, Co. Wicklow, Ireland
This filing incorporates by reference the Condensed Interim Unaudited Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the period ended June 30, 2025.
Key Financial Metrics
The provided text serves as a cover sheet and index for the financial statements. It does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached exhibits (99.1 and 99.2) which are not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period (June 30, 2024). Such analysis is contained within the Management's Discussion and Analysis (Exhibit 99.2).
Guidance, Outlook, and Risks
No specific guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the cover text. This information is expected to be found in the MD&A (Exhibit 99.2).
Investor Verification Checklist
- Verify the specific revenue and net income figures in Exhibit 99.1 (Condensed Interim Unaudited Consolidated Financial Statements).
- Review the MD&A in Exhibit 99.2 for details on liquidity, cash flows, and operational results.
- Confirm the impact of the appointment of Susan O'Connor as Interim Chief Financial Officer on financial reporting.
- Check for any specific risk factors or contingencies disclosed in the full MD&A document.